Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma
NCT03389802Phase 1Completed
- Sponsor
- Pediatric Brain Tumor Consortium
- Start
- Mar 2018
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of sotigalimab in glioblastoma multiforme (GBM), high-grade astrocytoma, primary central nervous system neoplasm (PCNS) and 3 more (2 arms), sponsored by Pediatric Brain Tumor Consortium. Primary endpoints: Number of Patients Who Experienced Dose-limiting Toxicities at 6 weeks, Maximum Tolerated Dose and/or Recommended Phase II Dose of APX005M in Stratum 1 at 6 weeks and 2 more. Started Mar 2018; status: completed.
02
Drugs
sotigalimab
03
Conditions
glioblastoma multiforme (GBM)high-grade astrocytomaprimary central nervous system neoplasm (PCNS)ependymomadiffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT03389802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03389802.